Skip to main content
SpringerLink
Log in

Consider the benefits and limitations of the available options when treating gastro-oesophageal reflux disease

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Hershcovici T, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs 2011; 71 (18): 2381–9.

    Article  PubMed  CAS  Google Scholar 

  2. Mayo Clinic. GERD [online]. Available from URL: http://www.mayoclinic.com [Accessed 2012 Feb 15].

  3. Carroll MW, Jacobson K. Gastroesophageal reflux disease in children and adolescents: when and how to treat. Pediatr Drugs 2012; 14 (2): 79–89.

    Article  Google Scholar 

  4. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 Jun; 112 (6): 1798–810.

    Article  PubMed  CAS  Google Scholar 

  5. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease. Where next? Aliment Pharmacol Ther 2005 Jul 15; 22 (2): 79–94.

    Article  CAS  Google Scholar 

  6. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012: 72 (4): 437–45.

    Article  PubMed  CAS  Google Scholar 

  7. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010 Jan; 105 (1): 34–41.

    Article  PubMed  CAS  Google Scholar 

  8. Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005 Jul 14; 11 (26): 4067–77.

    PubMed  CAS  Google Scholar 

  9. Johnson NJ, Boyd EJ, Mills JG, et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989 Jun; 3 (3): 259–66.

    Article  CAS  Google Scholar 

  10. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999 Jan; 94 (1): 92–7.

    Article  PubMed  CAS  Google Scholar 

  11. Sweetman SC, editor. Martindale thirty-sixth edition: the complete drug reference. London and Chicago: Pharmaceutical Press, 2009.

    Google Scholar 

  12. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No 63. London: BMJ Publishing Group Ltd and RPS Publishing, 2012 Mar.

  13. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011 May 18; 305 (19): 1969–77.

    Article  PubMed  CAS  Google Scholar 

  14. Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg 2010 Nov; 252 (5): 857–62.

    Article  PubMed  Google Scholar 

  15. Zou D, Chen WH, Iwakiri K, et al. Inhibition of transient lower esophageal sphincter relaxations by electrical acupoint stimulation. Am J Physiol Gastrointest Liver Physiol 2005 Aug; 289 (2): G197–201.

    Article  PubMed  CAS  Google Scholar 

  16. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007 Nov 15; 26 (10): 1333–44.

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Consider the benefits and limitations of the available options when treating gastro-oesophageal reflux disease. Drugs Ther Perspect 28, 14–16 (2012). https://doi.org/10.2165/11209280-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11209280-000000000-00000

Search

Navigation